SOURCE: StockCall


December 02, 2010 08:19 ET

Equity Research on Amgen Inc. and Acorda Therapeutics Inc. - Sneak Peek in the Biotech Industry

JOHANNESBURG, SOUTH AFRICA--(Marketwire - December 2, 2010) - offers investors comprehensive research on the biotechnology industry and has completed analytical research on Amgen Inc. (NASDAQ: AMGN) and Acorda Therapeutics Inc. (NASDAQ: ACOR). Register with us today at to have free access to these researches. 

Many big pharmaceutical and biotechnology companies are in hot waters with the onset of huge patent cliffs during the next three years. After cutting their budgets during their recent fiscal difficulties, many companies are beginning to search out other means besides R&D to secure their pipelines. This creates value for smaller companies in the sector with strong incoming product lines as they become takeover targets for larger companies looking to patch holes. In the aggressive acquisition market, many large companies are willing to marginally overpay in order to ensure they have something to work with coming down the pipeline. Register now at to have free access to our reports on the biotechnology industry. is an online platform where investors doing their due-diligence on the biotechnology industry can have easy and free access to our analyst research and opinions on Amgen Inc. and Acorda Therapeutics Inc.; investors and shareholders of these companies can simply register for a complimentary membership at

Good news for the sector involves the FDA's decision to provide patent protection for biosimilar generics. Previously, the Food and Drug Administration did not regulate the approval of biosimilar generic drugs, only drugs with chemical compounds. The FDA recently decided to give the biosimilars twelve years of patent protection signaling a victory for the sector. This had been an area of persistent governmental lobbying. Healthcare reform fee requirements, pay-for-delay patent reform, and coverage gaps remain issues the sector is working on in Washington. Visit to see how companies in this industry have grown over the past years and how they are expected to perform in the future.

Taking a look at earnings posted so far in Q3 2010, Amgen Inc. saw a decline in profit of 11% to $1.24 billion whilst Acorda Therapeutics Inc. reversed a loss incurred in the same quarter in 2009 to post a profit of $12.4 million for this quarter. Amgen Inc. and Acorda Therapeutics Inc. research reports are accessible for free by registering today at or

About is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.

Contact Information